---
document_datetime: 2025-05-08 11:49:19
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vimpat-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vimpat-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6409072
conversion_datetime: 2025-12-18 08:57:48.193185
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Vimpat

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - | 08/05/2025                          |                                             | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000268614                      | Update of the package leaflet with revised contact details of local representative.                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |             |                   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-------------------|
| Variation type IB /                   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - To align the English Product Information with the latest QRD templates (v.10.3 & v.10.4), correct typographical errors, remove erroneous information (colour of cup graduations), and propose corresponding updates in all EU languages, along with additional minor linguistic adjustments.                                                                                                                                               | 28/03/2025 |     | SmPC and PL | EMA/VR/0000247770 |
| Variation type IA / EMA/VR/0000248925 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a | 07/03/2025 | N/A |             |                   |

<div style=\"page-break-after: always\"></div>

| manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Refused A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|